Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

A Phase 1 Study of Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcitabine is a standard chemotherapy used for the treatment of pancreatic cancer.

Study Overview

• Status: Terminated
• Conditions: Pancreatic Adenocarcinoma
• Intervention / Treatment: Drug: Temsirolimus; Drug: Gemcitabine

Detailed Description

• Because this is a study to determine the highest doses of temsirolimus and gemcitabine that can be given safely together, groups of 3 subjects will be treated at gradually increasing doses of the drugs. Each group of 3 subjects must complete 4 weeks of treatment (1 cycle) before the following group of 3 subjects can start treatment at the higher dose of drug.
• Temsirolimus will be given intravenously every week of the 28 day treatment cycle (days 1, 8, 15, 22). Gemcitabine will be given intravenously every other week of the treatment cycle (days 1. 15).
• During the study, participants will have weekly clinic visits where the following tests and procedures may be performed: Physical exam; vital signs; urine test; blood tests.
• A CT scan will be performed after every 2 cycles (8 weeks) to assess teh response of the tumor to the study treatment.

• Study Type: Interventional
• Enrollment (Actual): 5
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Massachusetts General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Previously untreated metastatic pancreatic adenocarcinoma, histologically proven.
• Measurable disease by RECIST criteria
• ECOG Performance Status 0 or 1
• Male or female, 18 years of age or older
• Life expectancy of >/= 12 weeks
• AST and ALT </= 2.5 x ULN
• Total bilirubin </= 1.5 x ULN
• Serum albumin >/= 2.5g/dL
• Absolute neutrophil count >/= 1500/mm3; platelets >/= 100,000/mm3; hemoglobin >/= 9.0 g/dL
• Serum creatinine </= 1.5 x ULN
• Subjects with diabetes must have adequate glycemic control, with fasting serum glucose </= 1.5 x ULN
• Female patients of childbearing age and male patients with partners of childbearing age must agree to use adequate birth control measures during the course of the study and for at least one month following withdrawal from the study

Exclusion Criteria:

• Previously treatment with gemcitabine or chemoradiation
• Diagnosis of a second malignancy within the last 3 years, except for adequately treated basal cell carcinoma or squamous cell skin cancer
• Ongoing cardiac dysrhythmias of NCI CTCAE grade >/= 2, atrial fibrillation, QTc prolongation to > 450 msec for males and >470 msec for females
• Known immunodeficiency disorders or active infections requiring treatment
• Pregnancy or breastfeeding
• Known brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease
• Prior radiation therapy or major surgery within 4 weeks of study entry
• Prior radiation therapy to > 25% of the bone marrow
• Subjects receiving other experimental or alternative therapies during the course of the trial will be excluded
• History of prior hypersensitivity to polysorbate

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To determine the dose-limiting toxicities and maximal tolerated doses of gemcitabine combined with temsirolimus	2 years
To determine whether order of administration of the drugs affects the above	2 years
To determine the dosing regimen appropriate for Phase 2 studies of the combination	2 years

Secondary Outcome Measures

Outcome Measure
To document objective response rate and progression-free survival in patients treated with this combination

Collaborators and Investigators

• Sponsor: Massachusetts General Hospital
• Collaborators: Wyeth is now a wholly owned subsidiary of Pfizer; Dana-Farber Cancer Institute; Brigham and Women's Hospital
• Investigators: Principal Investigator: Eunice Kwak, MD, PhD, Massachusetts General Hospital

Study record dates

Study Major Dates

• Study Start: October 1, 2007
• Primary Completion (Actual): October 1, 2009
• Study Completion (Actual): October 1, 2009

Study Registration Dates

• First Submitted: December 28, 2007
• First Submitted That Met QC Criteria: January 11, 2008
• First Posted (Estimate): January 14, 2008

Study Record Updates

• Last Update Posted (Estimate): December 2, 2011
• Last Update Submitted That Met QC Criteria: December 1, 2011
• Last Verified: December 1, 2011

More Information

Terms related to this study

• Keywords: metastatic pancreatic cancer
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Digestive System Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antifungal Agents; Gemcitabine; Sirolimus
• Other Study ID Numbers: 07-115